Clinical Relevance and Prevalence of Polymorphisms in CYP3A5 and MDR1 Genes That Encode Tacrolimus Biotransformation Enzymes in Liver Transplant Recipients

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 2949-2951

  Barrera Pulido, L ^a   Aguilera Garcia I ^a   Docobo Perez F ^a   Alamo Martinez J M ^a   Pareja Ciuro F ^a   Nunez Roldan A ^a   Gomez Bravo M A ^a   Bernardos Rodriguez A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE FREQUENCY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TACROLIMUS; TISSUE DONORS; YOUNG ADULT;

EID: 55749084522     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.09.016     Document Type: Article

References (7)

1. Macphee I.A., Fredericks S., Tai T., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74 (2002) 1486
2. Goto M., Masuda S., Kiuchi T., et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14 (2004) 471
3. Songfeng Y., Lihua W., Jing J., et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 81 (2006) 46
4. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383
5. Johne A., Kopke K., Gerloff T., et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72 (2002) 584
6. Hesselink D.A., van Schaik R.H., van der Heiden, et al. Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmakocinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245
7. Wei-lin W., Jing J., Shu-sen Z., et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 12 (2006) 775